The gene therapy is the first treatment for active cerebral adrenoleukodystrophy, a fatal neurodegenerative disease that affects boys.
The FDA Friday granted accelerated approval of elivaldogne autotemcel (Skysona), also known as eli-cel, to slow the progression of neurologic dysfunction in boys aged 4 to 17 years who have early, active cerebral adrenoleukodystrophy (CALD).
The 1-time therapy will cost $3 million, according to bluebird bio.
CALD is caused by mutations in a gene called ABCD1 and typically occurs in boys between the ages of 3 and 12, with onset usually around age 7. The mutation affects the production of adrenoleukodystrophy protein (ALDP) and subsequently leads to accumulation of very long-chain fatty acids (VLCFAs), primarily in the white matter of the brain and spinal cord. This accumulation leads to the breakdown of myelin, the protective sheath of nerve cells.
Eli-cel adds functional copies of the ABCD1 gene in a patient's stem cells to help produce ALDP.
The approval comes after the drug received unanimous endorsement from a panel of outside advisers to the FDA in June. It is based on data from the phase 2/3 study ALD-102 (Starbeam) (N = 32) and phase 3 study ALD-104 (N = 35), both open-label, single-arm trials.
Participants had early, active CALD with elevated VLCFA values, a Loes score between 0.5 and 9 (inclusive), and gadolinium enhancement on MRI of demyelinating lesions. Additionally, patients were required to have a neurologic function score (NFS) of 1 or less, indicating limited changes in neurologic function. Efficacy was compared with a natural history population.
Per protocol, patients treated with eli-cel were assessed using the NFS and monitored for the emergence of 6 major functional disabilities (MFDs) associated with CALD progression: loss of communication, cortical blindness, requirement for tube feeding, total incontinence, wheelchair dependence, or complete loss of voluntary movement.
The accelerated approval is based on 24-month MFD-free survival. A post hoc enrichment analysis in symptomatic patients assessed MFD-free survival from onset of symptoms (NFS ≥ 1) in patients receiving eli-cel (n = 11) and no treatment (n = 7). Eli-cel treated patients had an estimated 72% likelihood of MFD-free survival at 24 months from time of first NFS ≥ 1, compared with untreated patients, who had only an estimated 43% likelihood of MFD-free survival.
The company also confirmed that the previous clinical hold on the eli-cel clinical development program has been lifted.
The approval is the company's second in about a month; in August, the FDA approved the first gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen